With over 100,000 patients with gastric conditions across our global network of 3,600 sites, Synexus is committed to the growing health concern and support of biopharmaceutical studies for gastrointestinal disorders. This has resulted in approximately 80 active clinical gastrointestinal studies being conducted via the assessment of more than 18,500 patients.
Areas of expertise include
Dr Radoslaw Janiak
President and COO
Specialist service offerings
The Indian market is emerging as an ideal source for Inflammatory Bowel Disease (IBD) patients. The network contains 57 high quality sites, including 12 that specialise in gastroenterology. Our local partner, S4 India, has in-depth country-specific knowledge and a pool of 400+ experienced and highly qualified investigators.
India has an IBD burden similar to the West, with an estimated population of 1.4 million, second to the U.S. and one of the largest across the globe. Synexus’ integrated approach provides instant access to the established predictable regulatory environment and infrastructure.
Together, Synexus and S4 can pave the way with all-inclusive guidance through study conduct, high-quality data, rapid start-up and streamlined processes.
Nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are creating widespread concern in the medical profession due to a low diagnosis rate and lack of approved therapies.
Synexus have been seeking out new tools and strategies to more efficiently recruit patients for these trials. We have access to a large pool of patients with co-morbidities such as obesity, Type 2 diabetes or other cardiovascular disease risk factors, which are known to be at a greater risk for NASH.
Working together on a focused approach ensures we can get the first patient to join the NAFLD/NASH study in the shortest time possible. We are not only recruiting patients, but also retaining them and increasing their motivation to participate in the right Synexus trial, which then enhances the overall quality of trial delivery.